Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US

References

• Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081–1086.
   PubMed Web of Science ®Google Scholar
• Lukowiak TM, Aizman L, Perz A, et al. Association of age, sex, race, and geographic region with variation of the ratio of basal cell to cutaneous squamous cell carcinomas in the United States. JAMA Dermatol. 2020;156(11):1192–1198. doi:10.1001/jamadermatol.2020.2571
   PubMed Web of Science ®Google Scholar
• Urban K, Mehrmal S, Uppal P, et al. The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990–2017. J Amer Acad Dermatology Internat. 2021 01;2:98–108.
   Google Scholar
• Garcovich S, Colloca G, Sollena P, et al. Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging Dis. 2017;8(5):643. doi:10.14336/AD.2017.0503
   PubMed Web of Science ®Google Scholar
• Burns C, Kubicki S, Nguyen QB, et al. Advances in cutaneous squamous cell carcinoma management. Cancers (Basel). 2022;14(15):3653. doi:10.3390/cancers14153653
   PubMed Web of Science ®Google Scholar
• Collins L, Quinn A, Stasko T. Skin cancer and immunosuppression. Dermatol Clin. 2019;37(1):83–94. doi:10.1016/j.det.2018.07.009.
   PubMed Web of Science ®Google Scholar
• Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns - results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96:34–43. doi:10.1016/j.ejca.2018.01.075
   PubMed Web of Science ®Google Scholar
• Schmults CD, Karia PS, Carter JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149(5):541–547.
   PubMed Web of Science ®Google Scholar
• Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg. 2007;33(8):885–899. doi:10.1111/j.1524-4725.2007.33190.x.
   PubMed Web of Science ®Google Scholar
• Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–720.
   PubMed Web of Science ®Google Scholar
• Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer [Research Support, U.S. Gov’t, P.H.S.]. J Clin Oncol. 2005;23(4):759–765. doi:10.1200/JCO.2005.02.155
   PubMed Web of Science ®Google Scholar
• Cowey CL, Robert NJ, Espirito JL, et al. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy. Cancer Med. 2020;9(20):7381–7387. doi:10.1002/cam4.3146
   PubMed Web of Science ®Google Scholar
• Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692–1696. doi:10.1002/1097-0142(19901015)66:8<1692:AID-CNCR2820660807>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67(8):2030–2032. doi:10.1002/1097-0142(19910415)67:8<2030:AID-CNCR2820670803>3.0.CO;2-K.
   PubMed Web of Science ®Google Scholar
• Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002;20(2):364–370. doi:10.1200/JCO.2002.20.2.364
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Keytruda® (pembrolizumab) injection, for intravenous use [US prescribing information] 2021 [cited 2023 Feb 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s096lbl.pdf
   Google Scholar
• Regeneron Pharmaceuticals Inc. LIBTAYO® [cemiplimab-rwlc] injection full US prescribing information updated 2021 Oct 2021 [cited 2023 Feb 6]]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: squamous cell skin cancer (version 2.2022) 2022 [May 10, 2022]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf
   Google Scholar
• MacMahon B. The National Death Index. Am J Public Health. 1983;73(11):1247–1248. doi:10.2105/AJPH.73.11.1247.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National Center for Health Statistics: national Death Index 2022 [May 24, 2023]. Available from: https://www.cdc.gov/nchs/ndi/index.htm
   Google Scholar
• Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013 Jun;68(6):957–966. doi:10.1016/j.jaad.2012.11.037.
   PubMed Web of Science ®Google Scholar
• Tokez S, Venables ZC, Hollestein LM, et al. Risk factors for metastatic cutaneous squamous cell carcinoma: refinement and replication based on 2 nationwide nested case-control studies. J Am Acad Dermatol. 2022;87(1):64–71. doi:10.1016/j.jaad.2022.02.056
   PubMed Web of Science ®Google Scholar
• Tokez S, Wakkee M, Kan W, et al. Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: a nationwide cancer registry study. J Am Acad Dermatol. 2022;86(2):331–338.
   PubMed Web of Science ®Google Scholar
• Amaral T, Osewold M, Presser D, et al. Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. J Eur Acad Dermatol Venereol. 2019;33(8):44–51.
   PubMedGoogle Scholar
• Keeping S, Xu Y, Chen C, et al. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Future Oncol. 2020;17(5):611–627. doi:10.2217/fon-2020-0823
   PubMed Web of Science ®Google Scholar
• Gold KA, Kies MS, William WN Jr., et al. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial. Cancer. 2018;124(10):2169–2173. doi:10.1002/cncr.31346
   PubMed Web of Science ®Google Scholar
• Picard A, Pedeutour F, Peyrade F, et al. Association of oncogenic mutations in patients with advanced cutaneous squamous cell carcinomas treated with cetuximab. JAMA Dermatol. 2017;153(4):291–298. doi:10.1001/jamadermatol.2017.0270
   PubMed Web of Science ®Google Scholar
• Rischin D, Khushalani NI, Schmults CD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021;9(8):e002757. doi:10.1136/jitc-2021-002757
   PubMed Web of Science ®Google Scholar
• Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021;32(10):1276–1285.
   PubMed Web of Science ®Google Scholar
• Haist M, Stege H, Lang BM, et al. Response to first-line treatment with immune-checkpoint inhibitors in patients with advanced cutaneous squamous cell carcinoma: a multicenter, retrospective analysis from the German ADOReg registry. Cancers (Basel). 2022;14(22):5543. doi:10.3390/cancers14225543
   PubMed Web of Science ®Google Scholar